Full Breakdown
mRNA Vaccine Halves Melanoma Recurrence Risk in Landmark Australian Trial
By Drooid · · How we work
Core Event
An Australian-led Phase 3 trial evaluated a personalized messenger-RNA (mRNA) vaccine added to the checkpoint inhibitor pembrolizumab (Keytruda) in patients with resected melanoma. Of the 1,137 participants, two-thirds received the vaccine while the remainder received a placebo injection. The interim analysis showed a 42 % reduction in the risk of melanoma recurrence or death for the vaccine group compared with pembrolizumab alone.
Background & Context
Melanoma was once a largely fatal disease; before checkpoint immunotherapies, most advanced-stage patients survived less than a year. Pembrolizumab has improved outcomes, yet roughly half of treated patients still die. The trial built on earlier work by Professor Georgina Long, who helped transform melanoma care with immunotherapy, and aimed to personalize treatment by targeting each tumor’s unique neoantigens.
Data & Statistics
- Participants: 1,137 patients, all previously surgically treated.
- Treatment arms: ~760 received the mRNA vaccine plus pembrolizumab; ~380 received pembrolizumab plus placebo.
- Two-year outcomes: 82 % of vaccine recipients were alive and melanoma-free versus 70 % of the pembrolizumab-only group.
- Neoantigen targeting: Vaccines encoded up to 34 patient-specific gene mutations.
Official Statements & Responses
Both highlighted the vaccine’s personalized approach as a departure from one-size-fits-all cancer therapies.
What’s Next
Researchers note that manufacturing individualized mRNA vaccines poses logistical challenges, especially for patients needing rapid treatment. Ongoing studies will assess whether the approach can benefit patients with active advanced melanoma or other tumor types, including early trials in lung and pancreatic cancers. The trial’s full results are slated for publication in *The New England Journal of Medicine* after the interim analysis was leaked ahead of the European Society for Medical Oncology presentation.